Minnesota looks to create abortion refuge for patients and providers; Moderna’s expected price single dose of COVID-19 sits at $130; FDA staff sees a "clinical benefit" in Biogen’s ALS drug.
Minnesota Seeks to Become Abortion Refuge State
Minnesota passed a bill that creates a refuge state for patients seeking abortions who live in restrictive states, according to The Associated Press. This bill will prohibit Minnesota from enforcing laws, subpoenas, judgments, or extradition requests from other states, such as Texas, against patients and providers who get or give abortions in Minnesota. Furthermore, another bill, currently working its way through Minnesota’s House and Senate, would repeal a list of state laws curtailing abortion rights; a district court judge already declared those laws unconstitutional, but the bill aims to keep an appellate court from overruling that decision.
Moderna’s $130 COVID-19 Vaccine
Moderna said the expected price for a single dose of its COVID-19 vaccine would be about $130 in the United States, Stephen Hoge, company president, told Reuters. The company previously said the range would be $110 to $130 a dose, similiar to the Pfizer-BioNTech vaccine. With the Biden administration ending the pandemic public health emergency in May, price negotiations are shifting to insurers and away from the government.
FDA Panel to Review Biogen’s ALS Drug
Staff at the FDA believe Biogen’s drug for amyotrophic lateral sclerosis (ALS) may have "clinical benefit" for patients with rare or aggressive forms of this disease, according to CNBC. On Wednesday, a panel of outside expert advisors will consider accelerated approval of Biogen’s drug tofersen, with the FDA expected to make its final decision on April 25, 2023. The panel will review the mixed evidence about the effectiveness and safety of the drug and will act on 2 questions the FDA has asked the panel to consider.
Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities
October 22nd 2024This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Cost Savings From an mHealth Tool for Improving Medication Adherence
October 21st 2024The Wellth smartphone app significantly increased medication adherence and lowered unnecessary health care utilization and costs over 9 months among Medicaid beneficiaries who were self-managing chronic conditions.
Read More
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More